Vcanbio scored an exit as the precision cancer treatment and diagnostics developer went public in an upsized offering priced well above its range.
Genetron Holdings, a China-based precision cancer treatment developer backed by gene engineering services provider Vcanbio Cell & Gene Engineering, has raised $256m in an initial public offering on the Nasdaq Global Market.
The offering consisted of 16 million American Depositary Shares (ADSs) – each representing five ordinary shares – priced at $16.00 each. The company had originally planned to issue 13 million ADSs priced at $11.50 to $13.50.
The IPO price included 1.31 million ADSs bought by Genetron’s shareholders,…
